Trial Profile
A Phase I Study to Evaluate the Safety, Biodistribution and Radiation Dosimetry of BFPET as a Potential Myocardial Perfusion Imaging (MPI) Agent for PET
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Apr 2017
Price :
$35
*
At a glance
- Drugs BFPET (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- Sponsors FluoroPharma
- 28 Apr 2017 New trial record